Nature CommunicationsFinerenone versus spironolactone in patients with chronic kidney disease and type 2 diabetes: a target trial emulationChung-An WangHsuan-Wen LaiJui-Yi ChenWei-Jie WangLi-Chun LinYen-Ling ChiuChung-Yi ChengVin-Cent Wu2025-10-31Full textDOI https://doi.org/10.1038/s41467-025-64640-3